Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering. The company filed its prospectus with the U.S. Securities and Exchange Commission on Aug. 17.
Copenhagen, Denmark-based Novo Nordisk acquired Bristol, UK-based Ziylo in a deal that could exceed $800 million.
Massachusetts in general and Boston, specifically Cambridge, is one of the two largest centers in the U.S. for biotech startups and life science companies (the other being the San Francisco Bay Area). Here’s a look at 13 Massachusetts life science companies that are showing both gains and losses—mostly gains—at the six-month mark.
Shares of Pompano Beach, Fla.-based BioStem Technologies are down more than 6 percent this morning following the company’s announcement it has launched a new life sciences subsidiary, the Amnion Division of BioStem Life Sciences focused on the development of amniotic tissue-based therapies.
Japan-based Astellas plunked down nearly $109 million to snap up privately-held gene therapy company Quethera Limited and its novel treatments for glaucoma and other ocular disorders.
Mississauga, Ontario-based Aralez Pharmaceuticals Inc. has entered into a stalking horse agreement to sell its assets to two separate companies, Nuvo Pharmaceuticals and Deerfield Management Companies. The beleaguered company will secure about $250 million for its assets from the sale as it files for bankruptcy.
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.
Shares of struggling OvaScience have dipped 8 percent this morning after the company announced it entered into an all-stock reverse merger agreement with privately-held Millendo Therapeutics, Inc. of Ann Arbor, Mich.
Cambridge, Mass.-based Sarepta Therapeutics expanded its gene therapy pipeline up to 11 in an equity deal with Lacerta Therapeutics. Investing $30 million into Alachua, Florida-based Lacerta Therapeutics, Sarepta gained access to the company’s AAV-based CNS-targeted gene therapies.
Two days after Boston Scientific laid off 85 employees at a Burlington, Mass. manufacturing site, the company forked over up to $160 million to acquire California stent maker Veniti, Inc. The deal marks the third acquisition for Boston Scientific in two months.